An interventional study of Placebo (Cellulose) and Creatine Monohydrate in Frailty, Sarcopenia and Aging, sponsored by Universidad de Burgos. Active, not recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Universidad de Burgos · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Frailty with a site in Spain — 46 open to participants now, 54 under way, none of them phase 3. Frailty · Spain.
Among the 132 studies in Frailty with a site in Spain, this one is the 69th largest by enrollment of the 96 interventional ones that give a count, is one of 21 that started in 2026, is one of 93 with no phase, reaches primary completion later than 31 of the 53 other live ones, and was the 104th registered.
1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →46 of the 132 studies in Frailty with a site in Spain are open now. Recruiting first, the newest first:
Universidad de Granada · Sites in Spain
Ages 65+
University of Vigo · Sites in Spain
Ages 70+
Fundacion Miguel Servet · Sites in Spain
Ages 75+
Alberto Bermejo Franco · Sites in Spain
Ages 70+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 21 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 83 across 772 interventional studies indexed under Frailty.
Median enrollment 90 across the 96 interventional studies, 432 across the 36 observational. Of the 60 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 132 have an industry lead sponsor. The 10 most frequent:
Universidad de Burgos is the lead sponsor of 25 studies on the registry; 4 are open to participants now.
Universidad de Burgos has 4 studies filed under Frailty — fewer than ten, so there is no comparison to draw.
11 of the studies in Frailty with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04926597Philipp SchuetzEffect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery | 2026-12 |
| NCT06556537Universidad de ZaragozaEffects of Physical Exercise on Frailty, Mental and Physical Health of Older Adults in Rural Areas. | 2026-12-20 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
| NCT07643064Alberto Bermejo FrancoMulticomponent Exercise and Comprehensive Geriatric Assessment Program (FRAIL+AP) for Frail Older Adults in Primary Care | 2026-12-31 |
| NCT07848802University of VigoPhysical Function and Fall Risk in Older Adults in the Lalín Frailty Prevention Program | 2027-01-15 |
Add all 11 to your calendar (.ics) → With an account.
Among the 132 studies in Frailty with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia and physical frailty are highly prevalent among institutionalized older adults and are major contributors to functional decline, reduced mobility, and loss of independence. Combined exercise and targeted nutritional strategies have emerged as promising approaches to mitigate these age-related impairments.
This randomized, double-blind, placebo-controlled, parallel-group clinical trial aims to evaluate the independent and combined effects of creatine monohydrate (CRE) and β-hydroxy-β-methylbutyrate (HMB), administered alongside a supervised multicomponent exercise program, on physical function, body composition, cognitive performance, and quality of life in institutionalized older adults with physical frailty and sarcopenia.
A total of 50 adults aged ≥65 years were enrolled and randomized to one of four intervention groups for 12 weeks: placebo plus exercise, creatine plus exercise, HMB plus exercise, or creatine plus HMB plus exercise. A supplement-free follow-up period will be conducted to evaluate the sustainability of intervention effects.
In addition to clinical and functional outcomes, the study incorporates molecular and biological assessments to explore mechanistic pathways underlying functional adaptation and interindividual variability in response to the interventions.
This randomized, double-blind, placebo-controlled, parallel-group clinical trial is designed to evaluate the independent and combined effects of creatine monohydrate (CRE) and β-hydroxy-β-methylbutyrate (HMB) supplementation when administered alongside a structured multicomponent exercise program in institutionalized older adults with physical frailty and sarcopenia. Sarcopenia and frailty are highly prevalent in this population and are associated with functional disability, increased health care utilization, and reduced quality of life. Nutritional strategies targeting muscle metabolism, when combined with systematic exercise, may attenuate functional decline and improve health outcomes in this vulnerable group.
Study Population and Design
A total of 50 institutionalized adults aged ≥65 years were enrolled from nursing homes in the province of Burgos (Spain). Participants were stratified by sex and randomized to one of four parallel intervention groups for a 12-week intervention period: placebo plus exercise, creatine plus exercise, HMB plus exercise, or creatine plus HMB plus exercise. All intervention groups will be followed by a supplement-free follow-up period to assess the persistence of intervention effects.
Intervention
Dietary supplementation will be administered once daily using identical sachets to ensure blinding and equivalent supplement volume across groups. Participants will receive a total of 6 g/day of powder, consisting of cellulose (placebo), creatine monohydrate, HMB, or their combinations, depending on group allocation. Supplement administration will be supervised by nursing staff and mixed with food or beverages according to standard procedures.
All participants will complete a supervised multicomponent exercise program conducted four times per week (\~60 minutes per session). Exercise sessions will include resistance, balance, coordination, and flexibility training, with intensity individually adapted according to functional capacity using the Borg Rating of Perceived Exertion Scale.
Outcomes and Assessments
Clinical, functional, cognitive, and quality-of-life assessments will be conducted at baseline, post-intervention (Week 12), and during follow-up. Primary and secondary outcome measures focus on physical performance, muscle strength, body composition, cognitive function, activities of daily living, nutritional status, and quality of life.
Molecular and Biological Assessments
In addition to clinical outcomes, the study incorporates biological and molecular assessments to explore mechanistic pathways underlying functional adaptation and interindividual variability in response to supplementation and exercise. Venous blood samples will be collected for the analysis of inflammatory markers, oxidative stress and antioxidant status, hormonal profiles, and circulating and exosomal molecular signatures related to muscle metabolism and neuromuscular function. Body composition parameters will be assessed using dual-energy X-ray absorptiometry (DXA).
Statistical Analysis
Statistical analyses will be conducted using mixed-effects models appropriate for parallel-group randomized designs, with treatment group, time, and their interaction as fixed effects, and sex and age included as covariates where appropriate. Post-hoc pairwise comparisons will be adjusted for multiple testing. Statistical significance will be set at p \< 0.05.
Ethics and Data Protection
The study was approved by the Ethics Committee of the University of Burgos (IR 24/2023). Written informed consent was obtained from all participants or their legal representatives. All data will be pseudonymized and managed in accordance with the General Data Protection Regulation (GDPR) and Spanish data protection laws.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a total of 6 g/day of powder consisting of 3 g/day of creatine monohydrate and 3 g/day of β-hydroxy-β-methylbutyrate (HMB), administered once daily, combined with a supervised multicomponent exercise program for 12 weeks.
Dietary Supplement: Creatine Monohydrate · Behavioral: Multicomponent Exercise Program · Dietary Supplement: β-Hydroxy-β-Methylbutyrate (HMB)
Participants receive a total of 6 g/day of cellulose (placebo), administered once daily, combined with a supervised multicomponent exercise program for 12 weeks.
Dietary Supplement: Placebo (Cellulose) · Behavioral: Multicomponent Exercise Program
Participants receive a total of 6 g/day of powder consisting of 3 g/day of creatine monohydrate and 3 g/day of cellulose (placebo filler), administered once daily, combined with a supervised multicomponent exercise program for 12 weeks.
Dietary Supplement: Placebo (Cellulose) · Dietary Supplement: Creatine Monohydrate · Behavioral: Multicomponent Exercise Program
Participants receive a total of 6 g/day of powder consisting of 3 g/day of β-hydroxy-β-methylbutyrate (HMB) and 3 g/day of cellulose (placebo filler), administered once daily, combined with a supervised multicomponent exercise program for 12 weeks.
Dietary Supplement: Placebo (Cellulose) · Behavioral: Multicomponent Exercise Program · Dietary Supplement: β-Hydroxy-β-Methylbutyrate (HMB)
Sachets containing cellulose used as placebo filler to match supplement volume, appearance, and taste. Administered once daily, mixed with yogurt or juice, during the intervention period.
Sachets containing creatine monohydrate used as an active dietary supplement. Administered once daily during the intervention period.
Supervised exercise sessions, 4 times per week (\~60 minutes each), including resistance, endurance, balance, coordination, and flexibility training. Intensity adapted to participants' functional status (Borg scale 6-9). Conducted throughout the 12-week intervention period.
Sachets containing calcium β-hydroxy-β-methylbutyrate used as an active dietary supplement. Administered once daily during the intervention period.
Short Physical Performance Battery (SPPB)
The SPPB assesses lower-extremity physical function through balance, gait speed, and chair stand components, generating a total score ranging from 0 to 12 (higher scores indicate better physical performance). Only the total score will be analyzed as the primary outcome.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Timed Up and Go (TUG)
Time in seconds to rise from a chair, walk 3 meters, turn around, return, and sit down. Lower times indicate better mobility and balance.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Appendicular Lean Mass (ALM, kg) by DEXA
Appendicular lean mass (sum of arms and legs lean tissue) measured in kilograms using DEXA. Higher values indicate greater muscle mass in limbs.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Grip Strength
Maximal isometric handgrip strength measured in kilograms using a validated hydraulic dynamometer (e.g., Jamar Plus+). Each test performed with the dominant hand in seated position, elbow at 90°. Best of three attempts recorded.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Leg and Back Isometric Strength
Maximal isometric strength of leg and back extensors assessed in kilograms using a back/leg dynamometer (e.g., Baseline Evaluation Dynamometer). Participants stand on the platform and pull a fixed bar upwards. Best of two attempts recorded.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Seated Arm Curl Test
Dynamic strength/endurance of upper limbs measured as the number of full arm curl repetitions in 30 seconds using a 2 kg dumbbell for women and a 4 kg dumbbell for men. Participants are seated upright without armrests.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Barthel Index
Measure of independence in activities of daily living (feeding, bathing, mobility, toileting, etc.). Score ranges from 0 (total dependence) to 100 (independent).
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Mini Nutritional Assessment (MNA)
Validated tool to screen and assess nutritional status in older adults. Score ranges from 0-30 (higher = better nutritional status).
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Cognitive Function - Mini-Mental State Examination (MMSE)
Cognitive function assessed using the Mini-Mental State Examination (MMSE). Scores range from 0 to 30, with higher scores indicating better cognition.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Quality of Life - World Health Organization Quality of Life-Brief (WHOQOL-BREF)
26-item validated questionnaire covering physical, psychological, social and environmental domains. Scores range from 26 to 130; higher scores indicate better perceived quality of life.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Total Lean Mass (kg) by DEXA
Whole-body lean soft tissue mass measured in kilograms using DEXA (Hologic Discovery or GE Lunar system) with manufacturer's software and standardized positioning. Higher values indicate greater muscle mass.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Total Fat Mass (percent body weight) by DEXA
Whole-body fat mass measured with DEXA and expressed as a percentage of total body weight. Higher values indicate greater adiposity.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Visceral Adipose Tissue (VAT, cm³) by DEXA
Visceral adipose tissue (VAT) volume estimated by DEXA in the android region of interest, expressed in cubic centimeters (cm³). Higher values indicate greater central adiposity.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Whole-Body Bone Mineral Density (BMD, g/cm²) by DEXA
Whole-body BMD measured by DEXA, expressed as grams per square centimeter (g/cm²). Higher values indicate greater bone mineral density.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Cognitive Function - MEC (Spanish Adaptation of MMSE)
Cognitive function assessed using the MEC (Spanish version of the MMSE). Scores range from 0 to 35, with higher scores indicating better cognition.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Number of Falls
Incidence of falls recorded by nursing staff during the study period. Unit: number of events per participant. Lower numbers indicate better outcomes.
Time frame: Baseline to 3-month follow-up
Number of Hospitalizations
Incidence of hospital admissions for any cause. Unit: number of events per participant. Lower numbers indicate better outcomes.
Time frame: Baseline to 3-month follow-up
Incidence of Respiratory and Urinary Infections
Number of documented respiratory and/or urinary tract infections. Unit: number of events per participant. Lower numbers indicate better outcomes.
Time frame: Baseline to 3-month follow-up
Incidence of Pressure Ulcers
Number of new pressure ulcers recorded by nursing staff. Lower numbers indicate better outcomes.
Time frame: Baseline to 3-month follow-up
Incidence of Urinary or Fecal Incontinence
Occurrence of urinary and/or fecal incontinence episodes recorded in clinical charts. Lower numbers indicate better outcomes.
Time frame: Baseline to 3-month follow-up
Serum C-reactive protein (CRP, mg/L)
CRP will be measured in serum samples using a high-sensitivity ELISA. Results expressed in mg/L. Higher values indicate greater systemic inflammation.
Time frame: Baseline, Week 12 (end of intervention)
Interleukin-6 (IL-6, pg/mL)
Serum IL-6 concentration will be measured by ELISA and expressed in pg/mL. Higher values indicate greater systemic inflammation.
Time frame: Baseline, Week 12 (end of intervention)
Tumor Necrosis Factor-alpha (TNF-α, pg/mL)
Serum TNF-α concentration will be determined by ELISA and expressed in pg/mL. Higher values indicate greater systemic inflammation.
Time frame: Baseline, Week 12 (end of intervention)
Reduced Glutathione (GSH, µmol/L)
Plasma reduced glutathione measured by colorimetric assay and expressed in µmol/L. Higher values indicate better antioxidant status.
Time frame: Baseline, Week 12 (end of intervention)
Oxidized Glutathione (GSSG, µmol/L)
Plasma oxidized glutathione measured by colorimetric assay and expressed in µmol/L. Higher values indicate greater oxidative stress.
Time frame: Baseline, Week 12 (end of intervention)
Thiobarbituric Acid Reactive Substances (TBARS, nmol MDA equivalents/mL plasma)
Lipid peroxidation index measured as TBARS and expressed in nmol MDA equivalents/mL of plasma. Higher values indicate greater oxidative stress.
Time frame: Baseline, Week 12 (end of intervention)
Malondialdehyde (MDA, µmol/L)
Plasma MDA determined spectrophotometrically and expressed in µmol/L. Higher values indicate greater oxidative stress.
Time frame: Baseline, Week 12 (end of intervention)
Total Antioxidant Capacity (TAC, mmol Trolox equivalents/L)
Plasma TAC measured using colorimetric assay and expressed as mmol Trolox equivalents/L. Higher values indicate better antioxidant defense.
Time frame: Baseline, Week 12 (end of intervention)
Relative expression levels of selected circulating microRNAs
Changes in the relative expression levels of selected circulating microRNAs associated with muscle metabolism, neuromuscular function, inflammation, oxidative stress, and anabolic signaling pathways. MicroRNAs will be quantified from peripheral blood samples using molecular profiling techniques.
Time frame: Baseline, Week 12 (end of intervention), and 3-month follow-up
Relative expression levels of selected exosome-derived microRNAs
Changes in the relative expression levels of selected exosome-derived microRNAs related to muscle function, inflammation, and metabolic regulation, analyzed from circulating extracellular vesicles isolated from plasma samples.
Time frame: Baseline and Week 12
Frequency of selected genetic variants related to creatine and HMB responsiveness
Analysis of the frequency of selected genetic variants related to muscle metabolism, anabolic signaling, and exercise responsiveness to explore interindividual variability in functional and molecular responses to creatine and HMB supplementation.
Time frame: Baseline
Relative abundance of selected circulating proteins involved in muscle and inflammatory responses
Changes in the relative abundance of selected circulating proteins involved in muscle metabolism, inflammation, oxidative stress, and functional adaptation in response to creatine and HMB supplementation combined with exercise. Protein abundance will be assessed using targeted proteomic approaches.
Time frame: Baseline and Week 12
Plan to share: Yes — De-identified individual participant data (IPD) underlying the published results of this trial (including baseline characteristics and outcome measures) will be made available to qualified researchers upon reasonable request. Data will be shared only after publication of the main results and following approval of a research proposal and data access agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Beginning 6 months after publication of the main results, for at least 5 years.
Access criteria: Researchers may request access by contacting the Principal Investigator (Prof. Juan Mielgo-Ayuso, Universidad de Burgos). Requests will be reviewed by the study steering committee. Access will be granted to qualified researchers whose proposals are scientifically and ethically sound, and who agree to sign a data access agreement.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 9 months is below that.
Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Creatine monohydrate · Beta-hydroxyisovaleric acid
Universidad de Burgos